These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 27509102)

  • 1. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
    Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R
    N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).
    Lenders M; Nordbeck P; Kurschat C; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; Stumpfe K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
    Clin Pharmacol Ther; 2020 Aug; 108(2):326-337. PubMed ID: 32198894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.
    Germain DP; Nicholls K; Giugliani R; Bichet DG; Hughes DA; Barisoni LM; Colvin RB; Jennette JC; Skuban N; Castelli JP; Benjamin E; Barth JA; Viereck C
    Genet Med; 2019 Sep; 21(9):1987-1997. PubMed ID: 30723321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migalastat: A Review in Fabry Disease.
    McCafferty EH; Scott LJ
    Drugs; 2019 Apr; 79(5):543-554. PubMed ID: 30875019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
    Feldt-Rasmussen U; Hughes D; Sunder-Plassmann G; Shankar S; Nedd K; Olivotto I; Ortiz D; Ohashi T; Hamazaki T; Skuban N; Yu J; Barth JA; Nicholls K
    Mol Genet Metab; 2020; 131(1-2):219-228. PubMed ID: 33012654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
    Narita I; Ohashi T; Sakai N; Hamazaki T; Skuban N; Castelli JP; Lagast H; Barth JA
    Clin Exp Nephrol; 2020 Feb; 24(2):157-166. PubMed ID: 31889231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
    Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
    J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.
    Schiffmann R; Bichet DG; Jovanovic A; Hughes DA; Giugliani R; Feldt-Rasmussen U; Shankar SP; Barisoni L; Colvin RB; Jennette JC; Holdbrook F; Mulberg A; Castelli JP; Skuban N; Barth JA; Nicholls K
    Orphanet J Rare Dis; 2018 Apr; 13(1):68. PubMed ID: 29703262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
    Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
    N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
    Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
    PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
    Giugliani R; Waldek S; Germain DP; Nicholls K; Bichet DG; Simosky JK; Bragat AC; Castelli JP; Benjamin ER; Boudes PF
    Mol Genet Metab; 2013 May; 109(1):86-92. PubMed ID: 23474038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry's Disease.
    Majid H; Verma N; Bhandari S; Gupta S; Nidhi
    Expert Opin Pharmacother; 2024 Apr; 25(6):769-782. PubMed ID: 38753367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
    Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
    Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.
    Benjamin ER; Della Valle MC; Wu X; Katz E; Pruthi F; Bond S; Bronfin B; Williams H; Yu J; Bichet DG; Germain DP; Giugliani R; Hughes D; Schiffmann R; Wilcox WR; Desnick RJ; Kirk J; Barth J; Barlow C; Valenzano KJ; Castelli J; Lockhart DJ
    Genet Med; 2017 Apr; 19(4):430-438. PubMed ID: 27657681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Migalastat: First Global Approval.
    Markham A
    Drugs; 2016 Jul; 76(11):1147-52. PubMed ID: 27351440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of plasma lyso-Gb
    Bichet DG; Aerts JM; Auray-Blais C; Maruyama H; Mehta AB; Skuban N; Krusinska E; Schiffmann R
    Genet Med; 2021 Jan; 23(1):192-201. PubMed ID: 32994552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
    Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.
    Riccio E; Zanfardino M; Ferreri L; Santoro C; Cocozza S; Capuano I; Imbriaco M; Feriozzi S; Pisani A;
    Eur J Hum Genet; 2020 Dec; 28(12):1662-1668. PubMed ID: 32647377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An atypical variant of Fabry's disease in men with left ventricular hypertrophy.
    Nakao S; Takenaka T; Maeda M; Kodama C; Tanaka A; Tahara M; Yoshida A; Kuriyama M; Hayashibe H; Sakuraba H
    N Engl J Med; 1995 Aug; 333(5):288-93. PubMed ID: 7596372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.